DOCSLIB.ORG

5 Drug Interactions You Don't Want to Miss

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
5 Drug Interactions You Don't Want to Miss Mary Onysko, PharmD, BCPS; Holly M. Anderson, PharmD; Songlin Cai, 5 drug interactions PharmD; Bradford T. Winslow, MD University of Wyoming, you don’t want to miss School of Pharmacy, Lara- mie (Drs. Onysko and Cai); Swedish Medical Center, These interactions can affect contraceptive efficacy, Englewood, Colo, and the Swedish Family Medi- increase bleeding risk, or lead to rhabdomyolysis. This cine Residency, Littleton, Colo (Drs. Anderson and practical guide can help you avoid trouble. Winslow) [email protected] The authors reported no potential conflict of interest here is a strong relationship between the number of relevant to this article. PRACTICE medications taken and the likelihood of a potentially RECOMMENDATIONS serious drug-drug interaction.1,2 Drug interaction soft- ❯ Recommend progesterone- T ware programs can help alert prescribers to potential prob- containing intrauterine lems, but these programs sometimes fail to detect important devices or long-acting proges- terone injections for women interactions or generate so many clinically insignificant alerts 3 using antiepileptic drugs. B that they become a nuisance. This review provides guidance about 5 clinically relevant drug interactions, including those ❯ Be aware that there is an in- that are common (TABLE 14-6)—and those that are less com- creased risk of gastrointestinal 6-10 bleeding when nonsteroidal mon, but no less important (TABLE 2 ). anti-inflammatory drugs are used with selective serotonin reuptake inhibitors. A a1. Antiepileptics & contraceptives Many antiepileptic medications decrease ❯ Do not prescribe novel oral anticoagulants for patients the efficacy of certain contraceptives taking carbamazepine, phe- Contraception management in women with epilepsy is critical nytoin, or phenobarbital. B due to potential maternal and fetal complications. Many an- tiepileptic drugs (AEDs), including carbamazepine, ethosuxi- ❯ Choose fenofibrate over gemfibrozil when combining mide, fosphenytoin, phenobarbital, phenytoin, primidone, 11 a fibrate and a statin. B topiramate, and valproate, are potentially teratogenic. A retrospective, observational study of 115 women of childbear- Strength of recommendation (SOR) ing age who had epilepsy and were seen at a neurology clinic A Good-quality patient-oriented 11 evidence found that 74% were not using documented contraception. B Inconsistent or limited-quality Of the minority of study participants using contraception, patient-oriented evidence most were using oral contraceptives (OCs) that could poten- C Consensus, usual practice, opinion, disease-oriented tially interact with AEDs. evidence, case series ❚ CYP inducers. Estrogen and progesterone are metabo- lized by the cytochrome P450 3A4 enzyme. Some AEDs induce this enzyme, which can enhance the metabolism of OCs, thus reducing their efficacy.12 It is not known, however, if this in- teraction results in increased pregnancy rates.13 Most newer AEDs (TABLE 36) do not induce cytochrome P450 3A4 and, thus, do not appear to affect OC efficacy, and may be safer for women with seizure disorders.12 While enzyme-inducing AEDs may decrease the efficacy of progesterone-only OCs and 680 THE JOURNAL OF FAMILY PRACTICE | NOVEMBER 2017 | VOL 66, NO 11 TABLE 1 Common and clinically relevant drug interactions4-6 Drug interaction Mechanism of Clinical relevance Recommendation interaction Nitrates Increases cyclic GMP in Severe hypotension, Contraindicated for smooth muscle, causing syncope, myocardial concomitant use. Do not PLUS vasodilation infarction, death prescribe together. phosphodiesterase type-5 inhibitors (eg, tadalafil, sildenafil citrate) Calcium/iron/magnesium/aluminum Chelation of metal ions Subtherapeutic antibi- Separate drug and supplements OR sucralfate to medication causes otic or thyroid medica- supplement administration reduced absorption tion levels in the body by 2 hours. PLUS fluoroquinolone or tetracycline antibiotics or levothyroxine Simvastatin Amiodarone is a CYP3A4 Increased risk of myopa- Avoid concomitant use and inhibitor; simvastatin is a thy or rhabdomyolysis switch to a different statin PLUS CYP3A4 substrate. with less interaction risk or amiodarone limit simvastatin dose to Co-administration can re- 20 mg/d. sult in increased systemic exposure to simvastatin. Lithium It is theorized that Lithium toxicity presents Avoid concomitant use of prostaglandins involved with diarrhea, lithium and NSAIDs; if both PLUS in renal clearance of vomiting, drowsiness, are necessary, obtain lithium NSAID or diuretic lithium are inhibited by muscle weakness, levels and assess for symp- NSAIDs, causing lithium impaired vision, and toms of toxicity. accumulation from impaired coordination. reduced clearance. Potassium chloride tablets Potassium chloride is Extended release and Potassium and anticholiner- acidic. Any medication wax matrix tablets have gics can be taken together. PLUS that could slow gastric been associated with Advise patients to take them anticholinergics emptying or dry oral severe esophageal with a full glass of water and gastric secretions damage and death; and remain upright for at could increase the risk however, there are no least 10 minutes after of potassium tablets clear data that swallowing the potassium. getting caught in the combining these Microencapsulated potas- gut and causing mucosal medications increases sium formulations (eg, damage. this risk.4 Micro-K, Klor-Con M) should cause less upper GI irritation than wax matrix formula- tions (eg, K-Tab, Klor-Con). GI, gastrointestinal; GMP, guanosine 3’5’ monophosphate; NSAID, nonsteroidal anti-inflammatory drug. the morning-after pill,12,14,15 progesterone- els and, therefore, may increase the risk of containing intrauterine devices (IUDs), long- seizures, but progesterone-only pills do not acting progesterone injections, and non-hor- produce this effect.12,16 monal contraceptive methods appear to be ❚ Do guidelines exist? There are no spe- unaffected.14-17 cific evidence-based guidelines that pertain ❚ OCs and seizure frequency. There is to the use of AEDs and contraception to- no strong evidence that OCs affect seizure gether, but some organizations have issued frequency in epileptic women, although recommendations. changes in hormone levels during the men- ❚ The American College of Obstetri- strual cycle do affect seizure susceptibility.12 cians and Gynecologists recommends us- Combination OCs decrease lamotrigine lev- ing a 30- to 35-mcg estrogen-containing OC JFPONLINE.COM VOL 66, NO 11 | NOVEMBER 2017 | THE JOURNAL OF FAMILY PRACTICE 681 TABLE 2 Medications with multiple interactions Medication Mechanism of interaction6 Clinical relevance Recommendation Amiodarone A substrate and inhibitor of many Bleeding has been reported Use extreme caution with CYP enzymes. Also inhibits OCT2 when used with warfarin; narrow therapeutic index and P-glycoprotein Torsades de pointes has or high-risk medications. occurred when given with some antiarrhythmics; bradycardia may occur when used with beta-blockers and calcium channel blockers.7 Digoxin Substrate for CYP3A4 and With a narrow therapeutic Close monitoring in elderly P-glycoprotein index, potentially life-threat- patients or those with ening cardiac adverse effects renal disease is can occur when combined with recommended. medications such as macrolide antibiotics or amiodarone.8 Methadone A substrate and inhibitor of many Fatalities have been associated Only prescribers with CYP enzymes; a significant CNS with benzodiazepines and extensive experience with depressant; may increase serotonin alcohol. Opiate withdrawal methadone should syndrome risk may occur when given with prescribe it. rifampin.9 Hepatitis C treatments P-glycoprotein/ABCB1 inhibitor, P-glycoprotein/ABCB1 inducers Avoid the use of PPIs at (ledipasvir/sofosbuvir; CYP3A4 substrate may decrease serum concen- doses greater than the elbasvir/grazoprevir) tration of ledipasvir/sofosbuvir; equivalent of omeprazole antacids may decrease serum 20 mg; avoid CYP3A4 concentration of ledipasvir.6 inducers.6 Rifampin Induces many CYP enzymes; Decreases the concentration of Use extreme caution with substrate and inducer of many medications such as war- narrow therapeutic index P-glycoprotein farin or oral contraceptives6 or high-risk medications. Theophylline Substrate and inhibitor of CYP1A2, Has been reported to reduce 375 drugs are known to CYP2E1, CYP3A4 the effect of benzodiazepines; interact with theophylline, macrolides may decrease which supports its decline theophylline concentrations.6 in popularity.10 Avoid using this agent unless all other options have failed. ABCB1, ATP-binding cassette sub-family B member 1; TP, adenosine triphosphate; CNS, central nervous system; CYP, cytochrome P450 enzyme; OCT2, organic cation transporter 2; PPIs, proton pump inhibitors. rather than a lower dose in women taking an considering IUDs and injectable contracep- enzyme-inducing AED. The group also rec- tive methods.21 ommends using condoms with OCs or using IUDs.18 ❚ The American Academy of Neurol- 2. SSRIs & NSAIDs. ogy suggests that women taking OCs and SSRIs increase the GI bleeding risk enzyme-inducing AEDs use an OC contain- associated with NSAIDs alone ing at least 50 mcg estrogen.19 Nonsteroidal anti-inflammatory drugs ❚ The National Institute for Health and (NSAIDs) and selective serotonin reuptake Care Excellence recommends that women inhibitors (SSRIs) are commonly prescribed taking enzyme-inducing AEDs avoid proges- worldwide.22,23 A well-established adverse tin-only pills.20 effect
Load more

Recommended publications
  • Anaesthesia and Past Use Of
    177 Correspondence were using LSD. It is more popular than other commonly Anaesthesia and past use of used hallucinogens whose quoted incidence of clients are: LSD ketamine 0.1% (super-K/vitamin K.I), psilocybin and psilocin 0.6% (the active alkaloids in the Mexican "magic To the Editor: mushroom"), and 3,4 methylenedioxymethamphetamine We report the case of a 43-yr-old lady who was admitted ~MDMA" 1% (ecstasy). The effects of the concurrent to the Day Surgery Unit for release of her carpal tunnel ingestion of LSD on anaesthesia are well described. 2-4 retinaculum. During the preoperative visit, she reported The long-term effects of the past use of LSD are largely no intercurrent illnesses, drug therapy or allergies. She unknown. We wonder if the hallucinations experienced did say, however, that she was frightened of general anaes- by our patient during anaesthesia were due to her LSD thesia, since she had experienced terrifying dreams during intake many years before. We would be interested to surgery under general anaesthesia on three occasions dur- know if others have had experience anaesthetising patients ing the previous ten years. On further questioning, she who are past users of phencyclidine-derived drugs. admitted that she had used lysergic acid diethylamide (LSD) during the late 1960's, the last occasion being 1968 Geoffrey N. Morris MRCGPFRCA when she had experienced characterstic hallucinations. Patrick T. Magee MSe FRCA She had not experienced hallucinations in the ensuing Anaesthetic Department years, except on the surgical occasions mentioned. Royal United Hospital One of the three previous operations had been per- Combe Park formed at our hospital and the anaesthetic record was Bath BA1 3NG checked.
    [Show full text]
  • Pharmacokinetic Interactions Between Herbal Medicines and Drugs: Their Mechanisms and Clinical Relevance
    life Review Pharmacokinetic Interactions between Herbal Medicines and Drugs: Their Mechanisms and Clinical Relevance Laura Rombolà 1 , Damiana Scuteri 1,2 , Straface Marilisa 1, Chizuko Watanabe 3, Luigi Antonio Morrone 1, Giacinto Bagetta 1,2,* and Maria Tiziana Corasaniti 4 1 Preclinical and Translational Pharmacology, Department of Pharmacy, Health and Nutritional Sciences, Section of Preclinical and Translational Pharmacology, University of Calabria, 87036 Rende, Italy; [email protected] (L.R.); [email protected] (D.S.); [email protected] (S.M.); [email protected] (L.A.M.) 2 Pharmacotechnology Documentation and Transfer Unit, Preclinical and Translational Pharmacology, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy 3 Department of Physiology and Anatomy, Tohoku Pharmaceutical University, 981-8558 Sendai, Japan; [email protected] 4 School of Hospital Pharmacy, University “Magna Graecia” of Catanzaro and Department of Health Sciences, University “Magna Graecia” of Catanzaro, 88100 Catanzaro, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-0984-493462 Received: 28 May 2020; Accepted: 30 June 2020; Published: 4 July 2020 Abstract: The therapeutic efficacy of a drug or its unexpected unwanted side effects may depend on the concurrent use of a medicinal plant. In particular, constituents in the medicinal plant extracts may influence drug bioavailability, metabolism and half-life, leading to drug toxicity or failure to obtain a therapeutic response. This narrative review focuses on clinical studies improving knowledge on the ability of selected herbal medicines to influence the pharmacokinetics of co-administered drugs. Moreover, in vitro studies are useful to anticipate potential herbal medicine-drug interactions.
    [Show full text]
  • The Differential Effects of Statins on the Metastatic Behaviour of Prostate Cancer
    British Journal of Cancer (2012) 106, 1689–1696 & 2012 Cancer Research UK All rights reserved 0007 – 0920/12 www.bjcancer.com The differential effects of statins on the metastatic behaviour of prostate cancer *,1 1 1 2,3 2,3 2,4 1,2,4 M Brown , C Hart , T Tawadros , V Ramani , V Sangar , M Lau and N Clarke 1 Genito Urinary Cancer Research Group, University of Manchester, Paterson Institute for Cancer Research, Manchester Academic Health Science Centre, 2 The Christie NHS Foundation Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK; Department of Urology, The Christie NHS Foundation 3 Trust, Wilmslow Road, Manchester M20 4BX, UK; Department of Urology, University Hospital of South Manchester NHS Trust, Manchester M23 9LT, 4 UK; Department of Urology, Salford Royal NHS Foundation Trust, Stott Lane, Manchester M6 8HD, UK BACKGROUND: Although statins do not affect the incidence of prostate cancer (CaP), usage reduces the risk of clinical progression and mortality. Although statins are known to downregulate the mevalonate pathway, the mechanism by which statins reduce CaP progression is unknown. METHODS: Bone marrow stroma (BMS) was isolated with ethical approval from consenting patients undergoing surgery for non- malignant disease. PC-3 binding, invasion and colony formation within BMS was assessed by standardised in vitro co-culture assays in the presence of different statins. RESULTS: Statins act directly on PC-3 cells with atorvastatin, mevastatin, simvastatin (1 mM) and rosuvastatin (5 mM), but not pravastatin, significantly reducing invasion towards BMS by an average of 66.68% (range 53.93–77.04%; Po0.05) and significantly reducing both 2 2 number (76.2±8.29 vs 122.9±2.48; P ¼ 0.0055) and size (0.2±0.0058 mm vs 0.27±0.012 mm ; P ¼ 0.0019) of colonies formed within BMS.
    [Show full text]
  • What Precautions Should We Use with Statins for Women of Childbearing
    CLINICAL INQUIRIES What precautions should we use with statins for women of childbearing age? Chaitany Patel, MD, Lisa Edgerton, PharmD New Hanover Regional Medical Center, Wilmington, North Carolina Donna Flake, MSLS, MSAS Coastal Area Health Education Center, Wilmington, NC EVIDENCE- BASED ANSWER Statins are contraindicated for women who are on its low tissue-penetration properties. pregnant or breastfeeding. Data evaluating statin Cholesterol-lowering with simvastatin 40 mg/d did use for women of childbearing age is limited; how- not disrupt menstrual cycles or effect luteal phase ever, they may be used cautiously with adequate duration (strength of recommendation: C). contraception. Pravastatin may be preferred based CLINICAL COMMENTARY Use statins only as a last resort Before reading this review, I had not been for women of childbearing age ® Dowdenaware Health of the serious Media effects of statin medications I try to follow the USPSTF recommendations and on the developing fetus. In conversations with not screen women aged <45 years without coro- my colleagues, I found that the adverse effects nary artery disease riskCopyright factors for Fhyperlipidemia.or personalof usestatins onlyduring pregnancy are not readily When a woman of any age needs treatment, my known. Such information needs to be more first-line therapy is lifestyle modification. Given the widely disseminated. risks of statin drugs to the developing fetus, Ariel Smits, MD women with childbearing potential should give Department of Family Medicine, Oregon Health & Science fully informed consent and be offered reliable University, Portland contraception before stating statin therapy. I Evidence summary anal, cardiac, tracheal, esophageal, renal, Hydroxymethyl glutaryl coenzyme A and limb deficiency (VACTERL associa- (HMG CoA) reductase inhibitors, com- tion), intrauterine growth retardation monly called statins, have been on the (IUGR), and demise in fetuses exposed market since the late 1980s.
    [Show full text]
  • Medications and Alcohol Craving
    Medications and Alcohol Craving Robert M. Swift, M.D., Ph.D. The use of medications as an adjunct to alcoholism treatment is based on the premise that craving and other manifestations of alcoholism are mediated by neurobiological mechanisms. Three of the four medications approved in the United States or Europe for treating alcoholism are reported to reduce craving; these include naltrexone (ReVia™), acamprosate, and tiapride. The remaining medication, disulfiram (Antabuse®), may also possess some anticraving activity. Additional medications that have been investigated include ritanserin, which has not been shown to decrease craving or drinking levels in humans, and ondansetron, which shows promise for treating early onset alcoholics, who generally respond poorly to psychosocial treatment alone. Use of anticraving medications in combination (e.g., naltrexone plus acamprosate) may enhance their effectiveness. Future studies should address such issues as optimal dosing regimens and the development of strategies to enhance patient compliance. KEY WORDS: AOD (alcohol and other drug) craving; anti alcohol craving agents; alcohol withdrawal agents; drug therapy; neurobiological theory; alcohol cue; disulfiram; naltrexone; calcium acetylhomotaurinate; dopamine; serotonin uptake inhibitors; buspirone; treatment outcome; reinforcement; neurotransmitters; patient assessment; literature review riteria for defining alcoholism Results of craving research are often tions (i.e., pharmacotherapy) to improve vary widely. Most definitions difficult to interpret,
    [Show full text]
  • Schizophrenia Care Guide
    August 2015 CCHCS/DHCS Care Guide: Schizophrenia SUMMARY DECISION SUPPORT PATIENT EDUCATION/SELF MANAGEMENT GOALS ALERTS Minimize frequency and severity of psychotic episodes Suicidal ideation or gestures Encourage medication adherence Abnormal movements Manage medication side effects Delusions Monitor as clinically appropriate Neuroleptic Malignant Syndrome Danger to self or others DIAGNOSTIC CRITERIA/EVALUATION (PER DSM V) 1. Rule out delirium or other medical illnesses mimicking schizophrenia (see page 5), medications or drugs of abuse causing psychosis (see page 6), other mental illness causes of psychosis, e.g., Bipolar Mania or Depression, Major Depression, PTSD, borderline personality disorder (see page 4). Ideas in patients (even odd ideas) that we disagree with can be learned and are therefore not necessarily signs of schizophrenia. Schizophrenia is a world-wide phenomenon that can occur in cultures with widely differing ideas. 2. Diagnosis is made based on the following: (Criteria A and B must be met) A. Two of the following symptoms/signs must be present over much of at least one month (unless treated), with a significant impact on social or occupational functioning, over at least a 6-month period of time: Delusions, Hallucinations, Disorganized Speech, Negative symptoms (social withdrawal, poverty of thought, etc.), severely disorganized or catatonic behavior. B. At least one of the symptoms/signs should be Delusions, Hallucinations, or Disorganized Speech. TREATMENT OPTIONS MEDICATIONS Informed consent for psychotropic
    [Show full text]
  • Prevalence of Drug Interactions in Hospitalized Elderly Patients: a Systematic Review
    Supplementary material Eur J Hosp Pharm Prevalence of drug interactions in hospitalized elderly patients: a systematic review Luciana Mello de Oliveira 1,2; Juliana do Amaral Carneiro Diel1; Alessandra Nunes3; Tatiane da Silva Dal Pizzol 1,2,3 1Programa de Pós-Graduação em Epidemiologia, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul. 2Programa de Pós-Graduação em Assistência Farmacêutica, Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul. 3Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul. Corresponding author: Luciana Mello de Oliveira – [email protected] and Tatiane da Silva Dal Pizzol - [email protected] Supplementary Table 3: Number of patients with interaction, number of DDI per patient with at least one DDI, drugs or drug classes mostly involved with DDI and drug combinations mostly involved with DDI. In cases which prevalence were described, we reported the three drugs mostly involved with drug interactions or the three drug combinations (or drug classes) mostly involved with DDI. ACE: angiotensin-converting enzyme. NA: not available. NSAID: non-steroidal anti-inflammatory drugs. PPI: proton-pump inhibitors. # of patients with # of DDI per patient with First autor interactions interaction Drugs or drug classes mostly involved with DDI Drug combinations mostly involved with DDI Barak-Tsarfir O, et al (61) Unclear: around 56 patients NA NA NA Warfarin; digitoxin; prednisolone antithrombotic agents; non-steroidal anti- 70 (evaluated only serious or inflammatory agents; angiotensin converting enzyme Blix HS, et al (29) contraindicated DDI) NA inhibitors N/A Serious: chlorpromazine + promethazine; chlorpromazine + haloperidol; haloperidol + promethazine; diazepam + phenobarbital; risperidone + haloperidol; carbamazepine + ketoconazole; carbamazepine + chlorpromazine; haloperidol + ketoconazole; chlorpromazine + ketoconazole; chlorpromazine + sodium phosphate.
    [Show full text]
  • Safety and Efficacy of a Continuous Infusion, Patient Controlled Anti
    Bone Marrow Transplantation, (1999) 24, 561–566 1999 Stockton Press All rights reserved 0268–3369/99 $15.00 http://www.stockton-press.co.uk/bmt Safety and efficacy of a continuous infusion, patient controlled anti- emetic pump to facilitate outpatient administration of high-dose chemotherapy SP Dix, MK Cord, SJ Howard, JL Coon, RJ Belt and RB Geller Blood and Marrow Transplant Program, Oncology and Hematology Associates and Saint Luke’s Hospital of Kansas City, Kansas City, MO, USA Summary: and colleagues1 described an outpatient BMT care model utilizing intensive clinic support following inpatient admin- We evaluated the combination of diphenhydramine, lor- istration of HDC. This approach facilitated early patient azepam, and dexamethasone delivered as a continuous discharge and significantly decreased the total number of i.v. infusion via an ambulatory infusion pump with days of hospitalization associated with BMT. More patient-activated intermittent dosing (BAD pump) for recently, equipped BMT centers have extended the out- prevention of acute and delayed nausea/vomiting in patient care approach to include administration of HDC in patients receiving high-dose chemotherapy (HDC) for the clinic setting. Success of the total outpatient care peripheral blood progenitor cell (PBPC) mobilization approach is dependent upon the availability of experienced (MOB) or prior to autologous PBPC rescue. The BAD staff and necessary resources as well as implementation of pump was titrated to patient response and tolerance, supportive care strategies designed to minimize morbidity and continued until the patient could tolerate oral anti- in the outpatient setting. emetics. Forty-four patients utilized the BAD pump Despite improvements in supportive care strategies, during 66 chemotherapy courses, 34 (52%) for MOB chemotherapy-induced nausea and vomiting continues to be and 32 (48%) for HDC with autologous PBPC rescue.
    [Show full text]
  • Chapter 25 Mechanisms of Action of Antiepileptic Drugs
    Chapter 25 Mechanisms of action of antiepileptic drugs GRAEME J. SILLS Department of Molecular and Clinical Pharmacology, University of Liverpool _________________________________________________________________________ Introduction The serendipitous discovery of the anticonvulsant properties of phenobarbital in 1912 marked the foundation of the modern pharmacotherapy of epilepsy. The subsequent 70 years saw the introduction of phenytoin, ethosuximide, carbamazepine, sodium valproate and a range of benzodiazepines. Collectively, these compounds have come to be regarded as the ‘established’ antiepileptic drugs (AEDs). A concerted period of development of drugs for epilepsy throughout the 1980s and 1990s has resulted (to date) in 16 new agents being licensed as add-on treatment for difficult-to-control adult and/or paediatric epilepsy, with some becoming available as monotherapy for newly diagnosed patients. Together, these have become known as the ‘modern’ AEDs. Throughout this period of unprecedented drug development, there have also been considerable advances in our understanding of how antiepileptic agents exert their effects at the cellular level. AEDs are neither preventive nor curative and are employed solely as a means of controlling symptoms (i.e. suppression of seizures). Recurrent seizure activity is the manifestation of an intermittent and excessive hyperexcitability of the nervous system and, while the pharmacological minutiae of currently marketed AEDs remain to be completely unravelled, these agents essentially redress the balance between neuronal excitation and inhibition. Three major classes of mechanism are recognised: modulation of voltage-gated ion channels; enhancement of gamma-aminobutyric acid (GABA)-mediated inhibitory neurotransmission; and attenuation of glutamate-mediated excitatory neurotransmission. The principal pharmacological targets of currently available AEDs are highlighted in Table 1 and discussed further below.
    [Show full text]
  • Effectiveness of Olanzapine for the Treatment of Breakthrough
    Effectiveness of Olanzapine for the Treatment of Breakthrough Chemotherapy Induced Nausea and Vomiting Suthan Chanthawong BPharm*, Suphat Subongkot PharmD*, Aumkhae Sookprasert MD** * Division of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, Thailand ** Department of Internal Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand Objective: To evaluate safety and efficacy of olanzapine for breakthrough emesis in addition to standard antiemetic regimen in cancer patients receiving highly emetogenic chemotherapy. Material and Method: A phase II prospective open label clinical trial was conducted in tertiary care based hospital. Forty-six cancer patients diagnosed with solid tumors were enrolled to receive at least one cycle of highly emetogenic chemotherapy (HEC) every two to four weeks. Each patient was provided standard antiemetic consisting of the generic form of ondansetron plus corticosteroids and metoclopramide according to clinical practice guideline. Olanzapine was administered as 5 mg orally every 12 hours for two doses in patients experiencing breakthrough emesis for at least one episode despite standard prevention. The efficacy and tolerability were evaluated every six hours for 24 hours (utilizing Index of Nausea, Vomiting and Retching: INVR tool). Results: Of 46 evaluable patients receiving HEC and additional olanzapine between September 2009 and July 2010, the complete response of breakthrough emesis, retching, and nausea control among patients were 60.9%, 71.7%, and 50.0%, respectively. Adverse events reported were mild and tolerable including dizziness, fatigue, and dyspepsia. Conclusion: Olanzapine is considered to be safe and effective treatment of breakthrough vomiting in cancer patients undergoing highly emetogenic chemotherapy in the present study. Keywords: Olanzapine, Chemotherapy induced nausea and vomiting, Breakthrough vomiting, Ondansetron, Metoclopramide, Dexamethasone J Med Assoc Thai 2014; 97 (3): 349-55 Full text.
    [Show full text]
  • “GABA” 'Bout? Pregabalin and Gabapentin Abuse
    3/19/18 What’s All the “GABA” ‘Bout? Pregabalin and Gabapentin Abuse Courtney Kominek, PharmD, BCPS, CPE Disclosures .Courtney Kominek, PharmD, BCPS, CPE –Axial Healthcare – Consultant .The views and opinions expressed in this presentation are those of the authors and do not necessarily reflect the official policy or position of any agency of the United States government, including the Department of Veterans Affairs. 1 3/19/18 Learning Objectives .Review the proposed mechanisms of action (MOA) for gabapentin and pregabalin. .Explain the proposed rationale as to why gabapentin and pregabalin have become drugs of abuse. .Identify signs and symptoms of withdrawal that an addicted or tolerant patient may experience upon abrupt discontinuation of gabapentin or pregabalin. .Discuss updates on changes in pain management given the increase in gabapentin and pregabalin abuse. Current Situation Opioid overdose public health crisis Rising use of nonopioid medications including gabapentin Opioids and concomitant gabapentin increase risk for overdose Reports of gabapentinoid abuse Changes in PDMP and scheduling at state level http://www.register-herald.com/news/manchin-asks-fda-dea-to-consider-rescheduling-gabapentin/article_442fa04b-7ed9-5bf8-8d19-b5440e9c278b.html 2 3/19/18 Gabapentin and Pregabalin: Pharmacology and Pharmacokinetics Fact or Alternate Fact? .Gabapentin and pregabalin work on GABA. 3 3/19/18 Mechanism of Action Structurally related to GABA and has GABA-mimetic properties Do not • Alter uptake or breakdown • Convert into GABA • Bind to GABAa or GABAB Binds to the α2-δ subunit of the voltage-gated calcium channel Reduces the Ca2+ -dependent release of pro-nociceptive neurotransmitters Decreases release of glutamate, NE, and substance P Dworkin RH et al.
    [Show full text]
  • An Update on the Efficacy of Anti-Inflammatory Agents for Patients with Schizophrenia: Cambridge.Org/Psm a Meta-Analysis
    Psychological Medicine An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: cambridge.org/psm a meta-analysis 1,2 2,3,4 2,5 6 Review Article N. Çakici , N. J. M. van Beveren , G. Judge-Hundal , M. M. Koola and I. E. C. Sommer5 Cite this article: Çakici N, van Beveren NJM, Judge-Hundal G, Koola MM, Sommer IEC 1Department of Psychiatry and Amsterdam Neuroscience, Academic Medical Center, Meibergdreef 9, 1105 AZ (2019). An update on the efficacy of anti- Amsterdam, the Netherlands; 2Antes Center for Mental Health Care, Albrandswaardsedijk 74, 3172 AA, Poortugaal, inflammatory agents for patients with 3 schizophrenia: a meta-analysis. Psychological the Netherlands; Department of Psychiatry, Erasmus Medical Center, Doctor Molewaterplein 40, 3015 GD 4 Medicine 49, 2307–2319. https://doi.org/ Rotterdam, the Netherlands; Department of Neuroscience, Erasmus Medical Center, Doctor Molewaterplein 40, 5 10.1017/S0033291719001995 3015 GD Rotterdam, the Netherlands; Department of Psychiatry and Biomedical Sciences of Cells and Systems, University Medical Center Groningen, Deusinglaan 2, 9713AW Groningen, the Netherlands and 6Department of Received: 13 February 2019 Psychiatry and Behavioral Sciences, George Washington University School of Medicine and Health Sciences, 2300I Revised: 4 July 2019 St NW, Washington, DC 20052, USA Accepted: 16 July 2019 First published online: 23 August 2019 Abstract Key words: Background. Accumulating evidence shows that a propensity towards a pro-inflammatory Add-on antipsychotic therapy; estrogens; fatty acids; minocycline; N-acetylcysteine status in the brain plays an important role in schizophrenia. Anti-inflammatory drugs might compensate this propensity. This study provides an update regarding the efficacy of Author for correspondence: agents with some anti-inflammatory actions for schizophrenia symptoms tested in rando- N.
    [Show full text]